By Fineline Cube Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.
Transaction Structure & Timeline
| Component | Detail |
|---|---|
| Buyer | Astorg (pan-European private equity firm) |
| Seller | Thermo Fisher Scientific Inc. (NYSE: TMO) |
| Total Consideration | USD 1.075 billion |
| Payment Structure | Cash + USD 50 million seller note |
| Expected Closing | Second half of 2026 |
| Conditions | Customary closing conditions and regulatory approvals |
Business Profile & Financial Metrics
| Metric | Detail |
|---|---|
| 2025 Revenue | USD 645 million |
| Business Segment | Specialty Diagnostics (Thermo Fisher) |
| Core Products | Antimicrobial susceptibility testing solutions |
| Additional Offerings | Culture media solutions |
| End Markets | Clinical diagnostics, pharmaceutical testing, food safety testing |
| Revenue Multiple | ~1.7x (based on 2025 revenue) |
Strategic Rationale
For Thermo Fisher Scientific:
- Portfolio Optimization: Focus on higher-growth, higher-margin businesses within life sciences and diagnostics
- Capital Allocation: Redirect resources to strategic priorities including bioproduction, genetic sciences, and laboratory products
- Operational Streamlining: Reduce complexity in Specialty Diagnostics segment
- Shareholder Value: Unlock value through disciplined portfolio management
For Astorg:
- Platform Investment: Acquire established microbiology business with strong market position
- Growth Potential: Leverage expertise in healthcare investments to accelerate business expansion
- Market Diversification: Access attractive end markets in clinical, pharma, and food safety testing
- Operational Improvement: Apply private equity operational expertise to enhance performance
Market Context & Industry Dynamics
- Microbiology Testing Market: Growing demand driven by antimicrobial resistance concerns, food safety regulations, and pharmaceutical quality control requirements
- Consolidation Trend: Continued M&A activity in life sciences tools and diagnostics sectors
- Private Equity Interest: Strong appetite for healthcare assets with stable cash flows and defensive characteristics
- Strategic Focus: Large life science companies increasingly focusing on core competencies and divesting non-strategic assets
Financial Impact & Forward Outlook
The transaction represents a strategic divestiture that aligns with Thermo Fisher’s disciplined approach to portfolio management. With USD 645 million in 2025 revenue, the microbiology business represented approximately 2-3% of Thermo Fisher’s total revenue base, making it a logical candidate for divestiture as the company focuses on larger-scale opportunities.
For Astorg, the acquisition provides a platform to build a standalone microbiology-focused company with established customer relationships across multiple attractive end markets. The business’s diversified revenue streams across clinical, pharmaceutical, and food safety applications provide resilience against market-specific downturns.
Forward-Looking Statements
This brief contains forward-looking statements regarding the transaction, regulatory approvals, and strategic implications. Actual outcomes may differ due to risks including regulatory decisions, closing conditions, and market dynamics.-Fineline Info & Tech